Elements · ← Yb Ytterbium · Hf Hafnium →
Radioactive lutetium-177 is attached to targeting molecules to treat certain cancers.
| Symbol | Lu |
|---|---|
| Atomic number | 71 |
| Standard atomic weight | 174.9667 |
| Group | none (lanthanide series) |
| Period | 6 |
| Block | f-block |
| Category | Lanthanide |
| Standard state | Solid |
| Discovered | 1907 |
Source: PubChem, Lutetium (periodic table data, retrieved 2026-10-19). Group and period follow the standard 18-column periodic table.
In the NETTER-1 phase 3 trial in 229 patients with advanced midgut neuroendocrine tumours, estimated 20-month progression-free survival was 65.2% with lutetium-177-Dotatate versus 10.8% with octreotide LAR alone.
Built / tested: 177Lu-Dotatate
As reported in: Strosberg, El-Haddad, Wolin et al. (2017). Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine. doi:10.1056/nejmoa1607427
In the VISION phase 3 trial in advanced PSMA-positive metastatic castration-resistant prostate cancer, adding lutetium-177-PSMA-617 to standard care prolonged imaging-based progression-free survival and overall survival.
Built / tested: 177Lu-PSMA-617
As reported in: Sartor, de Bono, Chi et al. (2021). Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine. doi:10.1056/nejmoa2107322
Found by name, common compounds and chemical formulas in each entry.
Search Google Patents for lutetium in biological and medical uses: all patents · recent applications (2022+)
A patent is a legal claim, not proof that something works. See the Patents page.